Imatinib in Adult Patients With Metastatic Ocular Melanoma (NCT00421317) | Clinical Trial Compass
TerminatedPhase 2
Imatinib in Adult Patients With Metastatic Ocular Melanoma
Stopped: Study stopped at the end of the first step
France13 participantsStarted 2005-12
Plain-language summary
The scope of the trial is to determinate the anti-tumoral activity of imatinib in metastatic ocular melanoma patients.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Metastatic ocular melanoma
* Age \> or = 18 years old
* Measurable metastases \> or = 10 mm according to RECIST criteria
* PS-WHO \< or = 1 or IK \> 70 percent
* Normal hepatic function
* PNN \> 1500/mm3, platelets \> or = 100 000/mm3
* Contraception
* Informed consent signed
Exclusion Criteria:
* Patient with two prior lines of systemic treatment (chemotherapy, immunotherapy or association)
* Other evolutive neoplasic disease
* Severe hepatic insufficiency
* Severe renal insufficiency
* Somatic or psychiatric co-morbidity incompatible with the protocol
* Leptomeningeal or cerebral metastatic dissemination
* Pregnant or lactating woman
* Other antitumoral treatment
* Patient participating to another clinical trial with an experimental drug
* Known hypersensitivity to Imatinib or one of its excipients
* Resecable single metastasis